BeiGene Enter into Agreement with Novartis

BeiGene announced that it has entered into an agreement with Novartis to regain full control over the worldwide development, manufacturing, and commercialisation rights for TEVIMBRA (tislelizumab).

Under the terms of the agreement, Novartis will extend essential transition services and support to BeiGene. This collaborative effort will facilitate the seamless continuation of key components within the TEVIMBRA development and commercialisation plan.

These crucial aspects include manufacturing, regulatory affairs, safety protocols, and clinical support. In return, BeiGene has committed to supplying Novartis with a continuous clinical supply of TEVIMBRA to bolster its ongoing clinical trials.

Under the previous agreement, BeiGene and Novartis had a joint development effort for TEVIMBRA in various countries, including the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. In addition, Novartis will take on responsibility for regulatory submissions and commercialisation rights in these licenced regions once regulatory approval is obtained.

TEVIMBRA, an IgG4 anti-PD-1 monoclonal antibody, designed to minimise its interaction with Fc-gamma (Fcγ) receptors on macrophages. This strategic design aims to enhance the body's immune response against tumours by facilitating the detection and elimination of cancerous cells by immune cells.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!